PMID- 22435404
OWN - NLM
STAT- MEDLINE
DCOM- 20120918
LR  - 20161018
IS  - 1939-1676 (Electronic)
IS  - 0891-6640 (Linking)
VI  - 26
IP  - 3
DP  - 2012 May-Jun
TI  - Sonoclot(R) evaluation of single- and multiple-dose subcutaneous unfractionated 
      heparin therapy in healthy adult dogs.
PG  - 631-8
LID - 10.1111/j.1939-1676.2012.00907.x [doi]
AB  - BACKGROUND: Heparin therapy is difficult to monitor due to variation in animal 
      response. While laboratory measurements of activated partial thromboplasin time 
      (aPTT) and Anti-Xa activity (AXA) accurately describe heparin effect, their 
      availability is limited. HYPOTHESIS: Sonoclot analysis would be as sensitive as 
      AXA and aPTT to monitor effects of unfractionated heparin (UFH) in healthy adult 
      dogs. ANIMALS: Six adult mixed-breed dogs. METHODS: A prospective study design 
      was employed. On day 1, baseline samples were collected (CBC, PT, aPTT, and 
      Sonoclot), and UFH (300 U/kg SC) was administered to 6 dogs following an IV 
      loading dose of 50 U/kg. Sonoclot and aPTT were performed hourly for 12 hours. 
      AXA was assayed at hours 3, 6, 9, and 12. UFH (300 U/kg q8 h SC) was administered 
      at 12 hours, and subsequently (q8 h) for 2 additional days. On day 4, a final 
      dose of UFH was administered, and a sampling protocol identical to day 1 was 
      performed. RESULTS: Sonoclot activated clotting time (ACT) and clot rate (CR) 
      correlated with AXA (R = 0.69, R = 0.65, respectively, P < .001), although to a 
      lesser degree than aPTT (R = 0.75, P < .001). Linear regression using ACT and CR 
      as covariates indicated a stronger correlation with AXA (R = 0.73, P < .001). ACT 
      values strongly correlated with aPTT (R = 0.87, P < .001). CONCLUSIONS AND 
      CLINICAL IMPORTANCE: Administration of UFH to healthy dogs results in progressive 
      changes in Sonoclot values. AXA was correlated with a combination of ACT and CR 
      and with aPTT. Sonoclot may play a role in monitoring UFH therapy; however, 
      prospective studies evaluating its utility in clinical cases are warranted.
CI  - Copyright (c) 2012 by the American College of Veterinary Internal Medicine.
FAU - Babski, D M
AU  - Babski DM
AD  - Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, 
      University of Georgia, Athens, GA 30602, USA.
FAU - Brainard, B M
AU  - Brainard BM
FAU - Ralph, A G
AU  - Ralph AG
FAU - Pittman, J R
AU  - Pittman JR
FAU - Koenig, A
AU  - Koenig A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120322
PL  - United States
TA  - J Vet Intern Med
JT  - Journal of veterinary internal medicine
JID - 8708660
RN  - 0 (Anticoagulants)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Animals
MH  - Anticoagulants/blood/*pharmacology
MH  - Blood Coagulation Tests/methods/*veterinary
MH  - Dogs/*blood
MH  - Female
MH  - Heparin/blood/*pharmacology
MH  - Male
MH  - Prospective Studies
MH  - ROC Curve
MH  - Sensitivity and Specificity
EDAT- 2012/03/23 06:00
MHDA- 2012/09/19 06:00
CRDT- 2012/03/23 06:00
PHST- 2011/08/26 00:00 [received]
PHST- 2011/11/16 00:00 [revised]
PHST- 2012/02/08 00:00 [accepted]
PHST- 2012/03/23 06:00 [entrez]
PHST- 2012/03/23 06:00 [pubmed]
PHST- 2012/09/19 06:00 [medline]
AID - 10.1111/j.1939-1676.2012.00907.x [doi]
PST - ppublish
SO  - J Vet Intern Med. 2012 May-Jun;26(3):631-8. doi: 
      10.1111/j.1939-1676.2012.00907.x. Epub 2012 Mar 22.